Topical eye treatment for daily use by post-menopausal women
Our first product candidate is based on a naturally occurring, endogenous molecule found in the body. In prior clinical trials, the molecule, when used as an active pharmaceutical ingredient, was found to be associated with the mechanism of tear film production. Redwood proposes to restore the natural levels of this molecule by administration by way of an eye drop. This treatment is thought to promote tear film production which is needed to properly lubricate the front of the eye. The Redwood team and other scientists have already confirmed the significant correlation between this active substance and its subsequent reduction of symptoms of Dry Eye Disease (DED) in human clinical trials.
Dry Eye Disease
Sufferers of dry eye experience dryness, pain, stinging, burning, redness, itchiness, blurred vision, mucus discharge and general discomfort in the front of the eye – impairing people in basic daily functions such as reading, operating machinery and driving an automobile. In its severest form it is even debilitating. If not treated, some cases of dry eye can lead to damage of the ocular surface and even potential blindness.
DED is caused by many factors including inflammation, dysfunction of glands & cells in and around the eye. Ageing, contact lens use and dry environments can increase the risk of obtaining DED. Patients are forced to used standard over-the-counter eye drops or a combination of other drugs and surgery to try to alleviate their symptoms with the hope of finding any type of effect. There is currently no product on the market today that addresses the root cause of DED.
We are currently looking for new products in need of topical slow-release administration to the eye that could benefit from use of our IntelliGel platform. For those with licensing inquiries for their own development programs, please contact us.